CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News CytoDyn is actually  a   biotech which has worked vigilantly but unsuccessfully to produce an one off therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix. In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in […]

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has worked vigilantly but unsuccessfully to produce an one off therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terms of potential indications.

CytoDyn's inventories of leronlimab are building up, whether they'll ever be being used is an open question.


While CYDY  happens to be dawdling, promote opportunities for leronlimab as a combination therapy in the treatment of multi-drug-resistant HIV have been closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my last few shares. My 1st CytoDyn article, "CytoDyn: What to be able to Do When It is Too Good to be able to Be True?", set out what follows prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a very promotional image in the Uptick Newswire job interview that I came away with a bad opinion of the company.

Irony of irony, my bad viewpoint of the business enterprise has grown steadily, however, the disappointment hasn't been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger at the moment still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) back in 2012, announced as follows:

CytoDyn Inc.... has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the therapy and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV infected subjects. Today's payment of $3.5 million transfers ownership of this know-how and also connected intellectual property coming from Progenics to CytoDyn, and also roughly 25 million mg of bulk drug substance.... milestone payments after commencement of a stage III clinical trial ($1.5 zillion) along with the very first brand new drug application approval ($five million), as well as royalty payments of five percent of net sales upon commercialization.

Since that moment, CytoDyn's helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to buy a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many indications and many therapies, it's this single therapies in addition to a "broad pipeline of indications" since it places it. I call some pipelines, "pipedots." In CytoDyn's situation it touts the leronlimab of its as a likely beneficial therapy of dozens of indications.

Its opening banner on its site (below) shows an active organization with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple publications in addition to multiple delivering presentations.

Could all of it be smoke cigarettes and mirrors? That's a question I've been asking myself through the very beginning of my interest in this particular business. Judging with the multiples of a huge number of various comments on listings accessible through Seeking Alpha's CytoDyn Summary page, I am far from alone in this question.

CytoDyn is a traditional battleground, or possibly some might say cult stock. Its adherents are fiercely shielding of its prospects, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *